Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- XENE
- Price
- 42.24
- Stock movement up
- +1.24 (3.02%)
- Company name
- Xenon Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.26B
- Ent value
- 3.21B
- Price/Sales
- 325.89
- Price/Book
- 5.83
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 13.41%
- 1 year return (CAGR)
- 8.36%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
XENE does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 325.89 |
| Price to Book | 5.83 |
| EV to Sales | 320.28 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 77.28M |
| EPS (TTM) | -3.87 |
| FCF per share (TTM) | -3.20 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 10.02M |
| Gross profit (TTM) | -68.93M |
| Operating income (TTM) | -340.78M |
| Net income (TTM) | -306.33M |
| EPS (TTM) | -3.87 |
| EPS (1y forward) | -4.57 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -688.18% |
| Operating margin (TTM) | -3402.36% |
| Profit margin (TTM) | -3058.45% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 104.51M |
| Net receivables | 812.00K |
| Total current assets | 480.14M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 15.85M |
| Total assets | 607.84M |
| Accounts payable | 4.55M |
| Short/Current long term debt | 8.33M |
| Total current liabilities | 38.34M |
| Total liabilities | 48.33M |
| Shareholder's equity | 559.51M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -252.02M |
| Capital expenditures (TTM) | 1.26M |
| Free cash flow (TTM) | -253.29M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -54.75% |
| Return on Assets | -50.40% |
| Return on Invested Capital | -54.60% |
| Cash Return on Invested Capital | -45.15% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 41.29 |
| Daily high | 42.75 |
| Daily low | 40.81 |
| Daily Volume | 1.26M |
| All-time high | 50.04 |
| 1y analyst estimate | 55.40 |
| Beta | 0.98 |
| EPS (TTM) | -3.87 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 26 Feb 2026 |
Downside potential
Loading...
Downside potential data
| XENE | S&P500 | |
| Current price drop from All-time high | -15.59% | -0.89% |
| Highest price drop | -43.59% | -19.00% |
| Date of highest drop | 8 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -24.09% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
3.26B
Marketcap category
Mid-cap
Description
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Employees
316
Website
Investor relations
-
SEC filings
CEO
Simon Neil Pimstone
Country
USA
City
Burnaby
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page